Abstract:BACKGROUND:The serotonin receptor 1A and 1B (HTR1A/1B) gene have been suggested to be involved in the pathogenesis of major depressive disorder (MDD) and the antidepressant treatment response. Gene expression differences were partly mediated by genetic polymorphism and DNA methylation which might be affected by environmental factors. In the present study, we attempt to identify whether HTR1A/1B DNA methylation and genetic polymorphism could predict antidepressant treatment response.METHODS:85 Chinese Han MDD patients were clinically assessed 8 weeks after of initiating escitalopram treatment for the first time. Antidepressant treatment response was assessed by changes in the Hamilton Depression Rating Scale-17 items (HAMD-17) score. The Life Events Scale (LES) and the Childhood Trauma Questionnaire (CTQ) were utilized as the assessment of previous life stress. The Illumina HiSeq platform was used to assess DNA methylation at 96 CpG sites located in HTR1A and HTR1B gene promoter regions. Six single nucleotide polymorphisms (SNPs) (HTR1A rs6294, rs116985176; HTR1B rs6296, rs6298, rs1228814, rs1778258) were genotype by using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) or PCR sequencing. Regression analyses were used to explore the relationship between DNA methylation and SNP and antidepressant response.RESULTS:We identified two CpG sites predictor of antidepressant treatment response (CpG 668, amplicon HTR1A_1, NC_000005.10, P = 0.025; CpG 1401, amplicon HTR1B_4, NC_000006.12, P = 0.033). The interaction of four CpG sites hypomethylation of HTR1A/1B with high recent stress might result in impaired antidepressant treatment response. What's more, the present data indicated that age, environments and antidepressant treatment might affect DNA methylation status. It was found that DNA methylation status could be influenced by antidepressant treatment in turn. However, HTR1A and HTR1B genotypes did not influence antidepressant response and DNA methylation status.CONCLUSIONS:The results suggest that HTR1A/1B DNA hypomethylation and its interaction with recent life stress might drive impaired antidepressant treatment response. Meanwhile, DNA methylation, in turn, was modified by antidepressant treatment and environments. Our results offer new evidence for the role of epigenetic and genetic polymorphism in pharmacological response to antidepressants.

A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C)

Serotonin transporter polymorphism alters citalopram effects on human pain responses to physical pain

Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment.

Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder

Polymorphisms in the HTR2A and HTR3A Genes Contribute to Pain in TMD Myalgia

Serotonin transporter gene polymorphism and treatment response to serotonin reuptake inhibitor (escitalopram) in depression: An open pilot study

Association Study of 5-HT2A Receptor Gene Polymorphism with Persistent Somatoform Pain Disorder and the Efficacy of Fluoxetine

Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study

Anxiety Symptom Remission is Associated with Genetic Variation of PTPRZ1 among Patients with Major Depressive Disorder Treated with Escitalopram

Genetic contributions to pain modulation in sickle cell: A focus on single nucleotide polymorphisms

Sex-stratified association of variants in the Serotonin 1A receptor gene with acute crisis pain among African American sickle cell disease patients

5-Htr1a And 5-Htr2a Genetic Polymorphisms And Ssri Antidepressant Response In Depressive Chinese Patients

Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial

Gene-Based Association Analysis Suggests Association of HTR2A With Antidepressant Treatment Response in Depressed Patients

A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder

DNA methylation of serotonin genes as predictive biomarkers of antidepressant treatment response

Experimental Study of the Analgesic Effect of the Antidepressant Escitalopram

Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder

HTR1A/1B DNA Methylation May Predict Escitalopram Treatment Response in Depressed Chinese Han Patients.

Allelic Variation in 5-HTTLPR and the Effects of Citalopram on the Emotional Neural Network.

The association of escitalopram efficacy with CYP2C19 and ABCB1 gene polymorphisms